Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

ABSTRACT: Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), differ markedly from conventional cancer therapeutics. At the time of article preparation, the US Food and Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel, all of which are IEC therapies based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), and additional products are expected to

SUBMITTER: Maus MV 

PROVIDER: S-EPMC7745688 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature